Immunomedics' Trodelvy Improves Survival in Patients With Pretreated Triple-Negative Breast Cancer

Jul 07, 2020

|

NEW YORK – Immunomedics said on Monday that its antibody-drug conjugate sacituzumab govitecan-hziy (Trodelvy) met its primary endpoint of progression-free survival in the confirmatory Phase III ASCENT trial of metastatic triple-negative breast cancer patients who did not have brain metastases and had received at least two prior therapies.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Breaking News

Aug

24

Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Sep

10

Featured Webinar

Development of RNA-Based Predictive Response Signatures as Companion Diagnostics

This webinar, Part 2 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will focus on the development of RNA-based companion diagnostics for oncology.

Menu

Immunomedics' Trodelvy Improves Survival in Patients With Pretreated Triple-Negative Breast Cancer

To read the full story....

Breaking News

Caris Life Sciences, Elevation Oncology Partner on Patient Enrollment for Tumor-Agnostic Drug Trial

Hemogenyx Partners With UPenn to Study CAR T-Cell Therapy in AML

T Cell Receptor Repertoire Linked to Anti-PD-1 Therapy Response in Hodgkin Lymphoma

Xcovery's Ensartinib Extends PFS in First-Line Advanced ALK-Positive NSCLC

Real-World Data Reinforces Survival Benefit of Sequential Gilotrif, Tagrisso in EGFR-Mutated NSCLC

Singapore's Avatamed Raises $1M in Seed Funding

Utility of Novel RNA-Based Tools in Oncology Drug Development

Development of RNA-Based Predictive Response Signatures as Companion Diagnostics

What's Popular?

Singapore's Avatamed Raises $1M in Seed Funding

Xcovery's Ensartinib Extends PFS in First-Line Advanced ALK-Positive NSCLC

Caris Life Sciences, Elevation Oncology Partner on Patient Enrollment for Tumor-Agnostic Drug Trial

Hemogenyx Partners With UPenn to Study CAR T-Cell Therapy in AML

Genentech's Tecentriq, Paclitaxel Combo Fails to Improve PFS in PD-L1-Positive TNBC

Sponsorships